Debiopharm Plots Synthetic Lethality Course
Scrip spoke with Debiopharm’s Luke Piggott about the Swiss biotech’s interest in synthetic lethality and strategy around development and partnering.
Scrip - March 20, 2026

New LDL-C Treatment Guidelines Tell Doctors To Consider Drug Costs
New ACC/AHA dyslipidemia treatment guidelines say prescribers should consider LDL cholesterol-lowering drugs’ costs, but Amgen and Esperion note the work they’ve done to ensure access to their products.
Scrip - March 20, 2026

Roche Drops Emugrobart In SMA And Lifts Scholar Rock’s Prospects
Underwhelming efficacy led to the myostatin inhibitor's discontinuation of in SMA and FSHD, but Roche will continue a separate study in obesity. Meanwhile, Scholar Rock’s rival apitegromab could soon be back on track for approval.
Scrip - March 20, 2026

Pipeline Watch: Seven Approvals And Eight Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - March 20, 2026

InflaRx Survival Hopes Rest On Izicopan
The German biotech hopes to start Phase IIb trials soon of the oral complement C5a inhibitor in the extremely competitive hidradenitis suppurativa market.
Scrip - March 20, 2026

Novartis Makes $3bn Bet On Synnovation’s PI3K? Inhibitor SNV4818
The deal, which is expected to close in the first half of 2026, includes $2bn upfront plus $1bn in milestone related payments.
Scrip - March 20, 2026

Natco’s 90% Cut Price Semaglutide Generic Sounds War Bugle In India
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Scrip - March 20, 2026

Screenless, Smartphone-Controlled Pump: MiniMed Flex Cleared By FDA Weeks After IPO
After its IPO, MiniMed has its first FDA clearance as a public company. The MiniMed Flex – smaller, screenless, and smartphone-controlled – is the product the newly independent diabetes firm needed to shift the conversation from market debut to market execution.
Medtech Insight - March 20, 2026

Verily Raises $300M To Advance Precision Health Platform As Independent Firm
Google spinout Verily has raised $300m to advance its AI-driven personalized healthcare platforms and become an independent company.
Medtech Insight - March 20, 2026

NICE To Reassess English Funding Rejections Of Leqembi And Kisunla After Successful Appeals
According to the health technology assessment institute, NICE, new cost-effectiveness thresholds – which are higher than those that applied when the original decisions were made – will apply when its committee reconsiders the appraisals for Eisai and Eli Lilly’s Alzheimer’s disease drugs.
Pink Sheet - March 20, 2026

MEPs Vote To Delay And Simplify AI Act Rules For Medical Devices
In an effort to streamline AI rules for high-risk systems and improve competitiveness, two European Parliament committees agreed amendments to the EU AI Act that will allow medtech companies to avoid double certification with notified bodies. A plenary vote takes place in late March.
Medtech Insight - March 20, 2026

CIR Panel Will Urge US Regulators To Take Role In Airbrush Product And Device Safety
The Expert Panel for Cosmetic Ingredient Safety wants data to better understand airbrush cosmetic products and devices, but does not expect it will receive it.
HBW Insight - March 20, 2026

Natco’s 90% Semaglutide Discount Sets Price Expectations In India
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow, as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Generics Bulletin - March 20, 2026

Iran War Could Threaten Long-Term Industry Sustainability
Amid “significant uncertainty” for the off-patent industry caused by the war in Iran, the IGBA has warned that a prolonged conflict “could make solvent supply a critical concern” while escalating costs and squeezed margins could affect the long-term sustainability of affordable medicines.
Generics Bulletin - March 20, 2026

Alvotech Pivots To Dual Sourcing Amid Regulatory Reset
Alvotech is shifting toward dual-source manufacturing and operational execution as it addresses FDA setbacks, expands its biosimilar pipeline and drives growth through global launches, with US approvals representing key upside to its 2026 outlook.
Generics Bulletin - March 20, 2026

Formycon Unlocks Global Markets For Its Eylea Biosimilar
Formycon expects its aflibercept biosimilar to enter European markets from the end of spring, as commercial paths also open up in Latin America and Asia Pacific countries.
Generics Bulletin - March 20, 2026

Execs On The Move: February 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - March 18, 2026

Adapt To Survive: Private Hospitals In A High-Pressure Landscape
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
In Vivo - March 18, 2026

An Irregular Regulatory Agency: Industry Contends With An Unpredictable FDA
A series of surprise rejections has made for an FDA that drug and vaccine manufacturers are finding much harder to read than in years past.
In Vivo - March 18, 2026